Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||GSK3052230||Phase I||Actionable||In a Phase I trial, GSK3052230 (FP-1039) resulted in some preliminary efficacy, including a 20% reduction in tumor volume in one patient with castration resistant prostate cancer and a best response of stable disease in 41.7% (15/36) of patients with advanced solid tumors (PMID: 26646757; NCT00687505).||26646757|